Chemomab Therapeutics Ltd. (CMMB)
Market Open
15 Jun, 14:47
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN $
1. 58
-0.07
-4.2424%
$
10.16M Market Cap
- P/E Ratio
- Div Yield
41,564 Volume
- Eps
$ 1.65
Previous Close Investors:
Want to track CMMB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Best Momentum Stocks to Buy for Oct. 23
PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.
Zacks | 7 months ago
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
Chemomab Therapeutics Ltd. CMMB on Thursday released results from the Open Label Extension (OLE) portion of the Phase 2 Spring trial assessing nebokitug for primary sclerosing cholangitis (PSC).
Benzinga | 1 year ago
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
Chemomab Therapeutics (NASDAQ: CMMB ) just reported results for the second quarter of 2024. Chemomab Therapeutics reported earnings per share of -26 cents.
Investorplace | 1 year ago
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks | 1 year ago
